Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ

Cancer

Volumn 118, Issue 24, 2012, Pages 6022-6030

  Arvold, Nils D ^a   Punglia, Rinaa S ^b   Hughes, Melissa E ^b   Jiang, Wei ^a   Edge, Stephen B ^c,d   Javid, Sara H ^e   Laronga, Christine ^f   Niland, Joyce C ^g   Theriault, Richard L ^h   Weeks, Jane C ^b   Wong, Yu Ning ^b   Lee, Sandra J ^b,i   Hassett, Michael J ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^h UNIVERSITY OF TEXAS   (United States)

ⁱ HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

breast conserving therapy; contralateral breast cancer; ductal carcinoma in situ; estrogen receptor; grade; lumpectomy; radiation; second breast cancer; tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER RADIOTHERAPY; DATA ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; PHENOTYPE; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; SECONDARY BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES;

EID: 84870703325     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27691     Document Type: Article

References (43)

1. Sumner WE 3rd, Koniaris LG, Snell SE, et al. Results of 23,810 cases of ductal carcinoma-in-situ. Ann Surg Oncol. 2007; 14: 1638-1643.
2. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002; 94: 1546-1554.
3. Virnig BA, Tuttle TM, Shamliyan T, et al. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010; 102: 170-178.
4. Ernster VL, Barclay J, Kerlikowske K, et al. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996; 275: 913-918.
5. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society; 2010. Available at: http://www.cancer.org/acs/groups/ content/@nho/documents/document/acspc-024113.pdf. Accessed November 15, 2011.
6. Morrow M, Schmidt R, Cregger B, et al. Preoperative evaluation of abnormal mammographic findings to avoid unnecessary breast biopsies. Arch Surg. 1994; 129: 1091-1096.
7. Alexander HR, Candela FC, Dershaw DD, et al. Needle-localized mammographic lesions. Results and evolving treatment strategy. Arch Surg. 1990; 125: 1441-1444.
8. Silverstein MJ, Gamagami P, Colburn WJ, et al. Nonpalpable breast lesions: diagnosis with slightly overpenetrated screen-film mammography and hook wire-directed biopsy in 1,014 cases. Radiology. 1989; 171: 633-638.
9. Wilhelm MC, Edge SB, Cole DD, et al. Nonpalpable invasive breast cancer. Ann Surg. 1991; 213: 600-603; discussion 603-605.
10. Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006; 24: 3381-3387.
11. Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003; 362: 95-102.
12. Emdin SO, Granstrand B, Ringberg A, et al. SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol. 2006; 45: 536-543.
13. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001; 28: 400-418.
14. Habel LA, Daling JR, Newcomb PA, et al. Risk of recurrence after ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 1998; 7: 689-696.
15. Waldman FM, DeVries S, Chew KL, et al. Chromosomal alterations in ductal carcinoma in situ and their in situ recurrences. J Natl Cancer Inst. 2000; 92: 313-320.
16. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998; 16: 441-452.
17. Habel LA, Moe RE, Daling JR, et al. Risk of contralateral breast cancer among women with carcinoma in situ of the breast. Ann Surg. 1997; 225: 69-75.
18. Warnberg F, Bergh J, Holmberg L,. Prognosis in women with a carcinoma in situ of the breast: a population-based study in Sweden. Cancer Epidemiol Biomarkers Prev. 1999; 8: 769-774.
19. Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) 8-year update of Protocol B-17: intraductal carcinoma. Cancer. 1999; 86: 429-438.
20. Price P, Sinnett HD, Gusterson B, et al. Duct carcinoma in situ: predictors of local recurrence and progression in patients treated by surgery alone. Br J Cancer. 1990; 61: 869-872.
21. Solin LJ, Kurtz J, Fourquet A, et al. Fifteen-year results of breast-conserving surgery and definitive irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol. 1996; 14: 754-763.
22. Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011; 103: 478-488.
23. Bijker N, Peterse JL, Duchateau L, et al. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer. 2001; 84: 539-544.
24. Bijker N, Peterse JL, Fentiman IS, et al. Effects of patient selection on the applicability of results from a randomized clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS. Br J Cancer. 2002; 87: 615-620.
25. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
26. Katz JN, Chang LC, Sangha O, et al. Can comorbidity be measured by questionnaire rather than medical record review? Med Care. 1996; 34: 73-84.
27. Smith GL, Smith BD, Haffty BG,. Rationalization and regionalization of treatment for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys. 2006; 65: 1397-1403.
28. Cutuli B, Lemanski C, Fourquet A, et al. Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience. Br J Cancer. 2009; 100: 1048-1054.
29. Yen TW, Hunt KK, Mirza NQ, et al. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer. 2004; 100: 942-949.
30. Yen TW, Kuerer HM, Ottesen RA, et al. Impact of randomized clinical trial results in the National Comprehensive Cancer Network on the use of tamoxifen after breast surgery for ductal carcinoma in situ. J Clin Oncol. 2007; 25: 3251-3258.
31. Zujewski JA, Harlan LC, Morrell DM, et al. Ductal carcinoma in situ: trends in treatment over time in the US. Breast Cancer Res Treat. 2011; 127: 251-257.
32. Smith BD, Haffty BG, Buchholz TA, et al. Effectiveness of radiation therapy in older women with ductal carcinoma in situ. J Natl Cancer Inst. 2006; 98: 1302-1310.
33. Rakovitch E, Pignol JP, Chartier C, et al. The management of ductal carcinoma in situ of the breast: a screened population-based analysis. Breast Cancer Res Treat. 2007; 101: 335-347.
34. Gilleard O, Goodman A, Cooper M, et al. The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ [serial online]. World J Surg Oncol. 2008; 6: 61.
35. MacAusland SG, Hepel JT, Chong FK, et al. An attempt to independently verify the utility of the Van Nuys prognostic index for ductal carcinoma in situ. Cancer. 2007; 110: 2648-2653.
36. Silverstein MJ,. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg. 2003; 186: 337-343.
37. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009; 27: 5319-5324.
38. Solin LF, Fourquet A, Vicini FA, et al. Mammographically detected ductal carcinoma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation: long-term outcome and prognostic significance of patient age and margin status. Int J Radiat Oncol Biol Phys. 2001; 50: 991-1002.
39. Cutuli B, Cohen-Solal-le Nir C, de Lafontan B, et al. Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers' experience. Int J Radiat Oncol Biol Phys. 2002; 53: 868-879.
40. Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol. 2001; 19: 2263-2271.
41. Vicini FA, Recht A,. Age at diagnosis and outcome for women with ductal carcinoma-in-situ of the breast: a critical review of the literature. J Clin Oncol. 2002; 20: 2736-2744.
42. Wong JS, Kaelin CM, Troyan SL, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol. 2006; 24: 1031-1036.
43. Motwani SB, Goyal S, Moran MS, et al. Ductal carcinoma in situ treated with breast-conserving surgery and radiotherapy: a comparison with ECOG study 5194. Cancer. 2011; 117: 1156-1162.